Caucasian patients with anti-EPO antibody-related PRCA have been successfully treated with CsA alone at a dose of 200 mg/d (or 100 mg twice daily) (Verhelst et al, 2004; Rossert et al, 2005). This evidence concerns the gene EPO and pure red-cell aplasia.